Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · see citing works

Pancreatic Cancer

Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202 · see citing works

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · see citing works

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · see citing works

Cancer nanomedicine: progress, challenges and opportunities

Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · see citing works

Renal clearance of quantum dots

Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476 · see citing works

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · see citing works

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848 · see citing works

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · see citing works

Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer

Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M. O., Bruns, C. J., & Heeschen, C. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,898 · see citing works

Cancer stem cells revisited

Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769 · see citing works

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681 · see citing works

Pancreatic cancer

Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570 · see citing works

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502 · see citing works

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size

Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429 · see citing works

Pancreatic cancer

Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212 · see citing works

Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats

Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149 · see citing works

Integrated genomic characterization of pancreatic ductal adenocarcinoma

Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019 · see citing works

Polymer conjugates as anticancer nanomedicines

Duncan, R. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1958 · Cited by 1,956 · see citing works

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · see citing works

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00986-1 · Cited by 1,222 · cited 2× · see citing works

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120 · see citing works

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115 · see citing works

An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms

Hruban, R. H., Takaori, K., Klimstra, D. S., Adsay, N. V., Albores-Saavedra, J., Biankin, A. V., Biankin, S. A., Compton, C., Fukushima, N., Furukawa, T., et al. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000126675.59108.80 · Cited by 1,091 · see citing works

Multistage nanoparticle delivery system for deep penetration into tumor tissue

Wong, C., Stylianopoulos, T., Cui, J., Martin, J. D., Chauhan, V. P., Jiang, W., Popović, Z., Jain, R. K., Bawendi, M. G., & Fukumura, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018382108 · Cited by 1,067 · see citing works

Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels

Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031 · see citing works

A paracrine requirement for hedgehog signalling in cancer

Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T. T.-L., Tian, H., Ahn, C. P., Marshall, D. C. L., Fu, L., Januario, T., Kallop, D. Y., et al. (2008) · Nature · doi:10.1038/nature07275 · Cited by 961 · see citing works

Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

Louvet, C., Labianca, R., Hammel, P. R., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M. P., Aitini, E., Taı̈eb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 948 · see citing works

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848 · see citing works

Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer

Ferrone, C. R., Marchegiani, G., Hong, T. S., Ryan, D. P., Deshpande, V., McDonnell, E., Sabbatino, F., Santos, D., Allen, J. N., Blaszkowsky, L. S., et al. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000867 · Cited by 841 · see citing works

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D. B., Steward, W. P., Harper, P., Dunn, J., Smith, C. T., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 822 · see citing works

Strategies for advancing cancer nanomedicine

Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 815 · see citing works

Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

Cutsem, E. V., de Velde, H. J. V., Karásek, P., Oettle, H., Vervenne, W. L., Szawlowski, A. W., Schöffski, P., Post, S., Verslype, C., Neumann, H.-J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.112 · Cited by 784 · see citing works

Delivery of molecular and cellular medicine to solid tumors

Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 775 · see citing works

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · see citing works

Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy

Li, H., Du, J., Du, X., Xu, C., Sun, C.-Y., Wang, H., Cao, Z.-T., Yang, X., Zhu, Y.-H., Nie, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522080113 · Cited by 725 · see citing works

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekäs, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1490 · Cited by 682 · see citing works

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657 · see citing works

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

Cutsem, E. V., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Laethem, J. V., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J. G. C. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 651 · see citing works

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 632 · see citing works

Recent advances of cocktail chemotherapy by combination drug delivery systems

Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625 · see citing works

Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.

Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., & Kataoka, K. (2003) · PubMed · Cited by 602 · see citing works

Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 601 · see citing works

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B. L. G., Bajetta, E., Schueller, J., Saletti, P., Bauer, J. A., Figer, A., Pestalozzi, B. C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0886 · Cited by 594 · see citing works

Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate

Lima, C. M. R., Green, M. R., Rotche, R., Miller, W. H., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., & Miller, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.082 · Cited by 587 · see citing works

Both p16 Ink4a and the p19 Arf -p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse

Bardeesy, N. M., Aguirre, A. J., Chu, G. C., Cheng, K., Lopez, L. V., Hezel, A. F., Feng, B., Brennan, C. W., Weissleder, R., Mahmood, U., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601273103 · Cited by 575 · see citing works

Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer

Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8719 · Cited by 561 · see citing works

Locally Advanced Pancreatic Cancer

Hackert, T., Sachsenmaier, M., Hinz, U., Schneider, L., Michalski, C. W., Springfeld, C., Strobel, O., Jäger, D., Ulrich, A. B., & Büchler, M. W. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001850 · Cited by 532 · see citing works

Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer

Bailey, J. M., Swanson, B. J., Hamada, T., Eggers, J. P., Singh, P. K., Caffrey, T. C., Ouellette, M. M., & Hollingsworth, M. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0291 · Cited by 520 · see citing works

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Hingorani, S. R., Zheng, L., Bullock, A. J., Seery, T. E., Harris, W. P., Sigal, D. S., Braiteh, F., Ritch, P. S., Zalupski, M. M., Bahary, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9564 · Cited by 514 · see citing works

Addressing the challenges of pancreatic cancer: Future directions for improving outcomes

Hidalgo, M. M., Cascinu, S., Kleeff, J. H., Labianca, R., Löhr, M. J., Neoptolemos, J. P., Real, F. X., Laethem, J. V., & Heinemann, V. (2014) · Pancreatology · doi:10.1016/j.pan.2014.10.001 · Cited by 507 · see citing works

Oncogenic KRAS signalling in pancreatic cancer

Eser, S., Schnieke, A., Schneider, G., & Saur, D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.215 · Cited by 504 · see citing works

Targeting kidney mesangium by nanoparticles of defined size

Choi, C. H. J., Zuckerman, J. E., Webster, P. C., & Davis, M. E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103573108 · Cited by 503 · see citing works

Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression

Lu, J., Liu, X., Liao, Y., Salazar, F. B., Sun, B., Jiang, W., Chang, C. H., Jiang, J., Wang, X., Wu, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01651-9 · Cited by 441 · see citing works

Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice

Meng, H., Wang, M., Liu, H., Liu, X., Situ, A., Wu, B., Ji, Z., Chang, C. H., & Nel, A. E. (2015) · ACS Nano · doi:10.1021/acsnano.5b00510 · Cited by 440 · see citing works

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

Poplin, E. A., Feng, Y., Berlin, J. D., Rothenberg, M. L., Höchster, H. S., Mitchell, E. P., Alberts, S. R., O'Dwyer, P. J., Haller, D. G., Catalano, P. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9007 · Cited by 437 · see citing works

Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma

Rasheed, Z. A., Yang, J., Wang, Q., Kowalski, J., Freed, I., Murter, C., Hong, S., Koorstra, J.-B. M., Rajeshkumar, N. V., He, X., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp535 · Cited by 437 · see citing works

Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats

Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602772 · Cited by 430 · see citing works

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Vaccaro, V., Sperduti, I., & Milella, M. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1107627 · Cited by 427 · see citing works

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Kindler, H. L., Ioka, T., Richel, D. J., Bennouna, J., Letourneau, R., Okusaka, T., Funakoshi, A., Furuse, J., Park, Y. S., Ohkawa, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70004-3 · Cited by 402 · see citing works

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours

Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390 · see citing works

c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target

Li, C., Wu, J., Hynes, M. J., Dosch, J. S., Sarkar, B., Welling, T. H., di Magliano, M. P., & Simeone, D. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.009 · Cited by 385 · see citing works

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.

Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., & Lopez, M. (2002) · PubMed · Cited by 384 · see citing works

Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives

Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.012 · Cited by 380 · see citing works

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

Infante, J. R., Somer, B. G., Park, J. O., Li, C., Scheulen, M. E., Kasubhai, S. M., Oh, D., Liu, Y., Redhu, S., Steplewski, K. M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.024 · Cited by 370 · see citing works

Combined Targeted Treatment to Eliminate Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer

Mueller, M., Hermann, P. C., Witthauer, J., Rubio‐Viqueira, B., Leicht, S. F., Huber, S. L., Ellwart, J. W., Mustafa, M., Bartenstein, P., D’Haese, J. G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.05.053 · Cited by 348 · see citing works

Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer

Hingorani, S. R., Harris, W. P., Beck, J. T., Berdov, B. A., Wagner, S. A., Pshevlotsky, E. M., Tjulandin, S., Gladkov, O. A., Holcombe, R. F., Korn, R. L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2010 · Cited by 335 · see citing works

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma

Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., & Lopez, M. (2002) · Cancer · doi:10.1002/cncr.10323 · Cited by 307 · see citing works

Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Kim, E. J.-H., Sahai, V., Abel, E. V., Griffith, K. A., Greenson, J. K., Takebe, N., Khan, G. N., Blau, J., Craig, R. A., Balis, U. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1269 · Cited by 306 · see citing works

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

Oettle, H., Richards, D., Ramanathan, R. K., Laethem, J. V., Peeters, M., Fuchs, M., Zimmermann, A. H., John, W. J., Hoff, D. V., Arning, M., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi309 · Cited by 305 · see citing works

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

Colucci, G., Labianca, R., Costanzo, F. D., Gebbia, V., Cartenì, G., Massidda, B., Dapretto, E., Manzione, L., Piazza, E., Sannicolò, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4433 · Cited by 303 · see citing works

Mucins in pancreatic cancer and its microenvironment

Kaur, S., Sushil Kumar, K., Momi, N., Sasson, A. R., & Batra, S. K. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.120 · Cited by 302 · see citing works

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

Álvarez, R., Musteanu, M., Garcia-Garcia, E., Lopez-Casas, P. P., Megı́as, D., Guerra, C. E., Muñoz, M., Quijano, Y., Cubillo, A., Rodríguez-Pascual, J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.415 · Cited by 294 · see citing works

Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors

Miao, L., Lin, C. M., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.017 · Cited by 264 · see citing works

Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer

Adiseshaiah, P. P., Crist, R. M., Hook, S. S., & McNeil, S. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.119 · Cited by 239 · see citing works

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

Gonçalvès, A., Gilabert, M., François, É., Dahan, L., Perrier, H., Lamy, R., Ré, D., Largillier, R., Gasmi, M., Tchiknavorian, X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds135 · Cited by 224 · see citing works

A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma

Ko, A. H., LoConte, N. K., Tempero, M. A., Walker, E. J., Kelley, R. K., Lewis, S., Chang, W., Kantoff, E., Vannier, M. W., Catenacci, D. V. T., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000458 · Cited by 223 · see citing works

Early Diagnosis of Pancreatic Cancer: Challenges and New Developments

Kaur, S., Baine, M. J., Jain, M., Sasson, A. R., & Batra, S. K. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.69 · Cited by 221 · see citing works

Precursor Lesions for Sporadic Pancreatic Cancer: PanIN, IPMN, and MCN

Distler, M., Aust, D. E., Weitz, J., Pilarsky, C. P., & Grützmann, R. (2014) · BioMed Research International · doi:10.1155/2014/474905 · Cited by 219 · see citing works

Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies

Chiorean, E. G., & Coveler, A. L. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s60328 · Cited by 214 · see citing works

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

Stathopoulos, G. P., Syrigos, K. N., Aravantinos, G., Polyzos, A., Papakotoulas, P., Fountzilas, G., Potamianou, A., Ziras, N., Boukovinas, J., Varthalitis, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603301 · Cited by 198 · see citing works

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197 · see citing works

Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer

Feldmann, G., Habbe, N., Dhara, S., Bisht, S., Alvarez, H., Fendrich, V., Beaty, R. M., Mullendore, M. E., Karikari, C. A., Bardeesy, N. M., et al. (2008) · Gut · doi:10.1136/gut.2007.148189 · Cited by 193 · see citing works

Current standards and new innovative approaches for treatment of pancreatic cancer

Conroy, T., Bachet, J., Ayav, A., Huguet, F., Lambert, A., Caramella, C., Maréchal, R., Laethem, J. V., & Ducreux, M. P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.026 · Cited by 188 · see citing works

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

Rougier, P. R., Riess, H. B., Manges, R., Karásek, P., Humblet, Y., Barone, C., Santoro, A., Assadourian, S., Hatteville, L., & Philip, P. A. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.002 · Cited by 184 · see citing works

Pancreatic Cancer Epidemiology, Detection, and Management

Zhang, Q., Zeng, L., Chen, Y., Lian, G., Qian, C., Chen, S., Li, J., & Huang, K. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/8962321 · Cited by 174 · see citing works

Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Sasahira, N., Hirano, K., Kogure, H., Kawakubo, K., Yagioka, H., Yashima, Y., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605955 · Cited by 172 · see citing works

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

Fuchs, C. S., Azevedo, S. J., Okusaka, T., Laethem, J. V., Lipton, L. R., Riess, H. B., Szczylik, C. A., Moore, M. J., Peeters, M., Bodoky, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv027 · Cited by 168 · see citing works

Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade

Zhang, Z., Duan, Q., Zhao, H., Liu, T., Wu, H., Shen, Q., Wang, C., & Yin, T. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.023 · Cited by 153 · see citing works

Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer

Rombouts, S. J. E., Walma, M. S., Vogel, J. A., van Rijssen, L. B., Wilmink, J. W., Mohammad, N. H., van Santvoort, H. C., Molenaar, I. Q., & Besselink, M. G. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5373-2 · Cited by 145 · see citing works

Current and Emerging Therapies in Metastatic Pancreatic Cancer

Manji, G. A., Olive, K. P., Saenger, Y. M., & Oberstein, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2319 · Cited by 145 · see citing works

Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles

Sunoqrot, S., Bugno, J., Lantvit, D. D., Burdette, J. E., & Hong, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.006 · Cited by 141 · see citing works

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience

Cloyd, J. M., Katz, M. H. G., Prakash, L., Varadhachary, G. R., Wolff, R. A., Shroff, R. T., Javle, M. M., Fogelman, D. R., Overman, M. J., Crane, C. H., et al. (2016) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-016-3265-1 · Cited by 141 · see citing works

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

Conroy, T., Hammel, P. R., Hebbar, M., Abdelghani, M. B., Wei, A. C.-C., Raoul, J., Choné, L., François, É., Artru, P., Biagi, J. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba4001 · Cited by 140 · see citing works

Pancreatic cancer stromal biology and therapy

Xie, D., & Xie, K. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.01.002 · Cited by 135 · see citing works

Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies

Teague, A. S., Lim, K., & Wang‐Gillam, A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014564775 · Cited by 133 · see citing works

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

Schultheis, B. S., Reuter, D., Ebert, M., Siveke, J. T., Kerkhoff, A., Berdel, W. E., Hofheinz, R., Behringer, D. M., Schmidt, W. E., Göker, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx343 · Cited by 131 · see citing works

Pancreatic cancer: A comprehensive review and update

Muniraj, T., Jamidar, P. A., & Aslanian, H. R. (2013) · Disease-a-Month · doi:10.1016/j.disamonth.2013.08.001 · Cited by 130 · see citing works

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

O’Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J. M., Coveler, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv264 · Cited by 130 · see citing works

Can nanomedicines kill cancer stem cells?

Zhao, Y., Alakhova, D. Y., & Kabanov, A. V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.016 · Cited by 128 · see citing works

Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells

Pelosi, E., Castelli, G., & Testa, U. (2017) · Biomedicines · doi:10.3390/biomedicines5040065 · Cited by 124 · see citing works

Loss of the Transcription Factor GLI1 Identifies a Signaling Network in the Tumor Microenvironment Mediating KRAS Oncogene-induced Transformation

Mills, L. D., Zhang, Y., Marler, R. J., Herreros‐Villanueva, M., Zhang, L., Almada, L. L., Couch, F. J., Wetmore, C., di Magliano, M. P., & Fernández-Zapico, M. E. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438846 · Cited by 119 · see citing works

Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) plus gemcitabine in patients with advanced solid tumors

Subbiah, V., Grilley-Olson, J. E., Combest, A. J., Sharma, N., Tran, R. H., Bobe, I., Osada, A., Takahashi, K., Balkissoon, J., Camp, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1114 · Cited by 118 · see citing works

Unraveling the journey of cancer stem cells from origin to metastasis

Nimmakayala, R. K., Batra, S. K., & Ponnusamy, M. P. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.10.006 · Cited by 115 · see citing works

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial

Wang, J. P., Wu, C., Yeh, Y.-C., Shyr, Y., Wu, Y.-Y., Kuo, C., Hung, Y., Chen, M., Lee, W., Luo, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4216 · Cited by 114 · see citing works

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

Van Cutsem, E., Hidalgo, M., Canon, J., Macarulla, T., Bazin, I., Poddubskaya, E., Manojlovic, N., Radenkovic, D., Verslype, C., Raymond, E., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31603 · Cited by 104 · see citing works

Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

Philip, P. A., Goldman, B. H., Ramanathan, R. K., Lenz, H., Lowy, A. M., Whitehead, R. P., Wakatsuki, T., Iqbal, S., Gaur, R., Benedetti, J., et al. (2014) · Cancer · doi:10.1002/cncr.28744 · Cited by 94 · see citing works

Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer

Meng, H., & Nel, A. E. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.014 · Cited by 92 · see citing works

Precursor Lesions of Pancreatic Cancer

Yonezawa, S., Higashi, M., Yamada, N., & Goto, M. (2008) · Gut and Liver · doi:10.5009/gnl.2008.2.3.137 · Cited by 91 · see citing works

Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians

Spadi, R. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.27 · Cited by 90 · see citing works

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

Glassman, D. C., Palmaira, R. L. D., Covington, C. M., Desai, A. M., Ku, G. Y., Li, J., Harding, J. J., Varghese, A. M., O'Reilly, E. M., & Yu, K. H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4605-1 · Cited by 89 · see citing works

Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer

Saif, M. W., Podoltsev, N. A., Rubin, M. S., Figueroa, J. A., Lee, M. Y., Kwon, J.-W., Rowen, E., Yu, J.-W., & Kerr, R. O. (2009) · Cancer Investigation · doi:10.3109/07357900903179591 · Cited by 89 · see citing works

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Chiorean, E. G., Hoff, D. D. V., Tabernero, J. M., El-Maraghi, R. H., Ma, W. W., Reni, M., Harris, M., Whorf, R. C., Liu, H. W., Li, J. S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.185 · Cited by 88 · see citing works

Pancreatic cancer stem cells – update and future perspectives

Lonardo, E., Hermann, P. C., & Heeschen, C. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.06.002 · Cited by 82 · see citing works

Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma

Khushman, M. M., Dempsey, N. G., Maldonado, J. C., Loaiza‐Bonilla, A., Velez, M., Carcas, L., Dammrich, D., Hurtado-Cordovi, J. M., Parajuli, R., Pollack, T., et al. (2015) · Pancreatology · doi:10.1016/j.pan.2015.08.010 · Cited by 80 · see citing works

Pancreatic cancer stem cells: New insight into a stubborn disease

Zhan, H., Xu, J., Wu, D., Zhang, T., & Hu, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.004 · Cited by 79 · see citing works

Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs

Baba, M., Matsumoto, Y., Kashio, A., Cabral, H., Nishiyama, N., Kataoka, K., & Yamasoba, T. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.026 · Cited by 76 · see citing works

Systemic Chemotherapy in Advanced Pancreatic Cancer

Lee, H. S., & Park, S. W. (2016) · Gut and Liver · doi:10.5009/gnl15465 · Cited by 70 · see citing works

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer

Bergmann, L., Maute, L., Heil, G., Rüssel, J., Weidmann, E., Köberle, D., Fuxius, S., Weigang-Köhler, K., Aulitzky, W. E., Wormann, B. J., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.10.010 · Cited by 63 · see citing works

Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma

Paniccia, A., Edil, B. H., Schulick, R. D., Byers, J. T., Meguid, C. L., Gajdos, C., & McCarter, M. D. (2014) · Medicine · doi:10.1097/md.0000000000000198 · Cited by 59 · see citing works

High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study.

Hingorani, S. R., Harris, W. P., Hendifar, A. E., Bullock, A. J., Wu, X., Huang, Y. F., & Jiang, P. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.4006 · Cited by 59 · see citing works

A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma

Halford, S. E. R., Yip, D., Karapetis, C. S., Strickland, A. H., Steger, A. C., Khawaja, H. T., & Harper, P. (2001) · Annals of Oncology · doi:10.1023/a:1012522120294 · Cited by 57 · see citing works

Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs)

Koorstra, J.-B. M., Feldmann, G., Habbe, N., & Maitra, A. (2008) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-008-0282-x · Cited by 54 · see citing works

A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).

Jesus‐Acosta, A. D., O'Dwyer, P. J., Ramanathan, R. K., Hoff, D. D. V., Maitra, A., Rasheed, Z. A., Zheng, L., Rajeshkumar, N. V., Le, D. T., Hoering, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.257 · Cited by 53 · see citing works

Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity

Sartor, O. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0437 · Cited by 52 · see citing works

Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study

Cascinu, S., Berardi, R., Sobrero, A. F., Bidoli, P., Labianca, R., Siena, S., Ferrari, D., Barni, S., Aitini, E., Zagonel, V., et al. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.09.020 · Cited by 51 · see citing works

A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

Ko, A. H., Murphy, P. B., Peyton, J. D., Shipley, D. L., Al-Hazzouri, A., Rodriguez, F. A., Womack, M. S., Xiong, H. Q., Waterhouse, D. M., Tempero, M. A., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0066 · Cited by 50 · see citing works

New targeted therapies in pancreatic cancer

Seicean, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i20.6127 · Cited by 48 · see citing works

Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years

Hall, B. R., Cannon, A. C., Atri, P., Wichman, C., Smith, L. M., Ganti, A. K., Are, C., Sasson, A. R., Sushil Kumar, K., & Batra, S. K. (2018) · Oncotarget · doi:10.18632/oncotarget.25036 · Cited by 47 · see citing works

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors

Beatty, G. L., Shahda, S., Beck, T., Uppal, N., Cohen, S. J., Donehower, R. C., Gabayan, A. E., Assad, A., Switzky, J. C., Zhen, H., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0665 · Cited by 46 · see citing works

Pancreatic cancer and FOLFIRINOX : a new era and new questions

Marsh, R., Talamonti, M., Katz, M. H. G., & Herman, J. M. (2015) · Cancer Medicine · doi:10.1002/cam4.433 · Cited by 44 · see citing works

“Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer.”

Godhi, S. A., Parasar, K., Saluja, S. S., & Mishra, P. K. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001322 · Cited by 43 · see citing works

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan

Ko, A. H. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s88084 · Cited by 42 · see citing works

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

Swain, S. M., Schneeweiß, A., Gianni, L., Gao, J. J., Stein, A., Waldron-Lynch, M., Heeson, S., Beattie, M. S., Yoo, B., Cortés, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw695 · Cited by 41 · see citing works

A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer.

Richards, D., Stephenson, J., Wolpin, B. M., Becerra, C., Hamm, J. T., Messersmith, W. A., Devens, S., Cushing, J., Schmalbach, T., & Fuchs, C. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.213 · Cited by 41 · see citing works

Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma

Ng, K., Hendifar, A. E., Starodub, A., Chaves, J. M., Yang, Y., Koh, B. D., Barbie, D. A., Hahn, W. C., & Fuchs, C. S. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0650-5 · Cited by 38 · see citing works

nab-Paclitaxel for the treatment of pancreatic cancer

Kim, G. (2017) · Cancer Management and Research · doi:10.2147/cmar.s127840 · Cited by 36 · see citing works

Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials

Au, M., Emeto, T. I., Power, J., Vangaveti, V., & Lai, H. C. (2016) · Biomedicines · doi:10.3390/biomedicines4030020 · Cited by 35 · see citing works

Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer

Kumar, V., Chaudhary, A., Dong, Y., Zhong, H. A., Mondal, G., Feng, L., Kumar, V., & Mahato, R. I. (2017) · Scientific Reports · doi:10.1038/s41598-017-01942-7 · Cited by 35 · see citing works

Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.

Cutsem, E. V., Lenz, H., Furuse, J., Tabernero, J. M., Heinemann, V., Ioka, T., Bazin, I. S., Ueno, M., Csőszi, T., Wasan, H. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.193 · Cited by 35 · see citing works

Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial

Ioka, T., Okusaka, T., Ohkawa, S., Boku, N., Sawaki, A., Fujii, Y., Kamei, Y., Takahashi, S., Namazu, K., Umeyama, Y., et al. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv011 · Cited by 34 · see citing works

Targeting angiogenesis in pancreatic cancer: rationale and pitfalls

Whipple, C. A., & Korc, M. (2008) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-008-0280-z · Cited by 32 · see citing works

Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy

Kipps, E., Young, K., & Starling, N. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016688816 · Cited by 32 · see citing works

Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?

Aprile, G., Negri, F., Giuliani, F., Carlo, E. D., Melisi, D., Simionato, F., Silvestris, N., Brunetti, O., Leone, F., Marino, D., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.025 · Cited by 32 · see citing works

NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis

Doi, T., Hamaguchi, T., Shitara, K., Iwasa, S., Shimada, Y., Harada, M., Naito, K., Hayashi, N., Masada, A., & Ohtsu, A. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3254-4 · Cited by 32 · see citing works

Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer

Rahman, F. A. U., Ali, S., & Saif, M. W. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17705328 · Cited by 30 · see citing works

Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.

Chen, L., Hoff, D. D. V., Li, C., Wang‐Gillam, A., Bodoky, G., Dean, A. P., Shan, Y., Jameson, G., Macarulla, T. M., Lee, K.-H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.234 · Cited by 27 · see citing works

Driver mutations

Korc, M. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.6.13128 · Cited by 26 · see citing works

Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

O'Reilly, E. M., Sahai, V., Bendell, J. C., Bullock, A. J., LoConte, N. K., Hatoum, H. A., Ritch, P. S., Hool, H., Leach, J. W., Sanchez, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.279 · Cited by 20 · see citing works

Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: A meta-analysis

Tian, W., Ding, W., Kim, S., Xu, X., Pan, M., & Chen, S. (2013) · Pancreatology · doi:10.1016/j.pan.2013.04.195 · Cited by 20 · see citing works

Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

Messersmith, W. A., Cohen, S., Shahda, S., Lenz, H., Weekes, C. D., Dotan, E., Denlinger, C. S., O’Neil, B. H., Kapoun, A. M., Zhang, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw371.69 · Cited by 20 · see citing works

A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.

Catenacci, D. V. T., Bahary, N., Edelman, M. J., Nattam, S. R., Marsh, R., Kaubisch, A., Wallace, J. A., Cohen, D. J., Stiff, P. J., Sleckman, B. G., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.4022 · Cited by 20 · see citing works

A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer.

Sahora, K., Schindl, M., Kuehrer, I., Eisenhut, A., Werba, G., Brostjan, C., Telek, B., Ba‐Ssalamah, A., Stift, J., SCHOPPMANN, S. F., et al. (2014) · PubMed · Cited by 19 · see citing works

Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations

Wang‐Gillam, A., Hoff, D. D. V., Siveke, J. T., Hubner, R. A., Belanger, B., Pipas, J. M., & Chen, L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1607 · Cited by 14 · see citing works

A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study

Cohen, S. J., O’Neil, B. H., Berlin, J. D., Ames, P., McKinley, M., Horan, J. D., Catalano, P. M., Davies, A. M., Weekes, C. D., & Leichman, L. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2981-2 · Cited by 13 · see citing works

Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

Katopodis, O., Souglakos, J., Stathopoulos, E., Christopoulou, A. N., Kontopodis, E., Kotsakis, A. P., Kalbakis, K., Kentepozidis, N. K., Polyzos, A., Hatzidaki, D., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2509-6 · Cited by 12 · see citing works

Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

Weekes, C. D., Berlin, J. D., Lenz, H., O’Neil, B. H., Messersmith, W. A., Cohen, S., Dendinger, C., Shahda, S., Kapoun, A. M., Zhang, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw368.10 · Cited by 12 · see citing works

A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC).

Ko, A. H., Murray, J. H., Horgan, K. E., Dauer, J., Curley, M., Baum, J., Louis, C. U., & Lugovskoy, A. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.tps481 · Cited by 11 · see citing works

Erratum: Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Chiorean, E. G., Hoff, D. D. V., Tabernero, J. M., El-Maraghi, R. H., Ma, W. W., Reni, M., Harris, M., Whorf, R. C., Liu, H. W., Li, J. S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.306 · Cited by 11 · see citing works

New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer.

Jutric, Z., & Melstrom, L. G. (2017) · PubMed · Cited by 9 · see citing works

Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer

Pijnappel, E. N., Klaassen, R., van der Lee, K. S., van Empel, M. P., Richel, D. J., Legdeur, M. C. J. C., Nederveen, A. J., van Laarhoven, H. W. M., & Wilmink, H. W. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz247.022 · Cited by 6 · see citing works

A Phase I study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastasized pancreatic cancer

Lee, K., Molenaar, R. J., Klaassen, R., Bijlsma, M. F., Weterman, M. J., Richel, D. J., Wymenga, M., van Laarhoven, H. W. M., & Wilmink, J. W. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx369.143 · Cited by 6 · see citing works

A phase II study of gemcitabine, oxaliplatin, and erlotinib (GEMOX-T) combination chemotherapy in previously untreated patients with locally advanced unresectable or metastatic pancreatic cancer.

Yun, J., Kim, H. J., Kim, K. H., Kim, S. H., Kim, H. J., Lee, S., Bae, S. B., Kim, C. K., Lee, N.-S., Lee, K. T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.e15260 · Cited by 4 · see citing works

A phase IB study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: An Academic GI Cancer Consortium (AGICC) study.

Leichman, L. P., O’Neil, B. H., Berlin, J. D., Weekes, C. D., Ames, P., McKinley, M., Davies, A. M., & Cohen, S. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.4052 · Cited by 3 · see citing works

Evofosfamide combined with gemcitabine/nab-paclitaxel in patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma (PAC): Results of a phase I trial.

Borad, M. J., Kwak, E. L., Wang‐Gillam, A., Ibrahim, A. B., Aldridge, J., & Olszanski, A. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4114 · Cited by 2 · see citing works

Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment

Tarannum, M., & Vivero-Escoto, J. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114357 · Cited by 76 · see citing works

Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies

Natu, J., & Nagaraju, G. P. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216382 · Cited by 73 · see citing works

Pathway-Based Drug-Repurposing Schemes in Cancer: The Role of Translational Bioinformatics

Lemus, E. H., & Martínez-García, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.605680 · Cited by 55 · see citing works

AI-driven discovery of synergistic drug combinations against pancreatic cancer

Pourmousa, M., Jain, S., Barnaeva, E. S., Jin, W., Hochuli, J. E., Itkin, Z., Maxfield, T., Melo-Filho, C. C., Thieme, A., Wilson, K. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56818-6 · Cited by 34 · see citing works

Photodynamic eradication of intratumoral microbiota with bacteria‐targeted micelles overcomes gemcitabine resistance of pancreatic cancer

Liu, R., Yang, H., Qu, S., Yang, P., Zhi, X., Xu, Y., Dai, Z., & Qian, L. (2023) · Aggregate · doi:10.1002/agt2.423 · Cited by 33 · see citing works

Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer

Dókus, L. E., Lajkó, E., Ranđelović, I., Mező, D., Schlosser, G., Kőhidai, L., Tóvári, J., & Mező, G. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060576 · Cited by 33 · see citing works

Gelatin-Based Injectable Hydrogel/Microgel Composite as a Combinational Dual Drug Delivery System for Local Co-delivery of Curcumin and 5-Fluorouracil in Synergistic Therapy of Colorectal Cancer

Pakian, S., Radmanesh, F., Abandansari, H. S., & Nabid, M. R. (2022) · ACS Applied Polymer Materials · doi:10.1021/acsapm.2c01188 · Cited by 29 · see citing works

Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response

Höfer, S., Frasch, L., Brajkovic, S., Putzker, K., Lewis, J., Schürmann, H., Leone, V., Sakhteman, A., The, M., Bayer, F. P., et al. (2025) · Molecular Systems Biology · doi:10.1038/s44320-025-00085-6 · Cited by 27 · see citing works

Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer

Lu, T., & Prakash, J. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s279192 · Cited by 26 · see citing works

Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma

Afaq, F., Agarwal, S., Bajpai, P., Diffalha, S. A., Kim, H., Peter, S., Khushman, M. M., Chauhan, S. C., Mukherjee, P., Varambally, S., et al. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100951 · Cited by 26 · see citing works

Nanocarriers containing platinum compounds for combination chemotherapy

Fang, G., Zhang, A., Zhu, L., Wang, Q., Sun, F., & Tang, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1050928 · Cited by 22 · see citing works

Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer

Lei, F., Xi, X., Rachagani, S., Seshacharyulu, P., Talmon, G. A., Ponnusamy, M. P., Batra, S. K., & Bronich, T. K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.029 · Cited by 16 · see citing works

Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium

Ogobuiro, I. C., Collier, A. L., Khan, K., Silva, I. D. C., Kwon, D., Wilson, G. C., Schwartz, P. B., Parikh, A. A., Hammill, C. W., Kim, H. J., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12741-4 · Cited by 16 · see citing works

Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells

Sevrin, T., Imoto, H., Robertson, S. A., Rauch, N., Dyn'ko, U., Koubova, K., Wynne, K. J., Kölch, W., Rukhlenko, O. S., & Kholodenko, B. Ν. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114710 · Cited by 14 · see citing works

Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer

Gautam, S. K., Dalal, V., Sajja, B. R., Gupta, S., Gulati, M., Dwivedi, N. V., Aithal, A., Cox, J. L., Rachagani, S., Liu, Y., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215801 · Cited by 12 · see citing works

Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma

Yang, X., Lu, Y., Xu, J., Du, Y., & Yu, R. (2023) · Molecules · doi:10.3390/molecules28031506 · Cited by 12 · see citing works

Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer

Bai, J., Majjigapu, S. R., Sordat, B., Poty, S., Vogel, P., Elías‐Rodríguez, P., Moreno‐Vargas, A. J., Carmona, A. T., Caffa, I., Ghanem, M. S., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114504 · Cited by 11 · see citing works

Ligand-installed polymeric nanocarriers for combination chemotherapy of EGFR-positive ovarian cancer

Xi, X., Lei, F., Gao, K., Li, J., Liu, R., Karpf, A. R., & Bronich, T. K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.033 · Cited by 11 · see citing works

Carfilzomib and Paclitaxel Co-Loaded Protein Nanoparticles an Effective Therapy Against Pancreatic Adenocarcinomas

Cheng, W.-T., Ho, H., Lin, S.-Y., Liu, D.-Z., Chen, L.-C., & Sheu, M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s331210 · Cited by 11 · see citing works

Immune checkpoint inhibitors in pancreatic adenocarcinoma: a systematic review and meta analysis of clinical outcomes

Al-Khinji, A., Al-Korbi, N., Al-Kuwari, S., Al-Hor, A., & Malouche, D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1569884 · Cited by 10 · see citing works

Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A

Szydlak, R. (2024) · Biomolecules · doi:10.3390/biom14091178 · Cited by 10 · see citing works

Tumor microenvironment interactions with cancer stem cells in pancreatic ductal adenocarcinoma

Palma, A. M., Bushnell, G. G., Wicha, M. S., & Gogna, R. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.007 · Cited by 8 · see citing works

MISP-mediated enhancement of pancreatic cancer growth through the Wnt/β-catenin signaling pathway is suppressed by Fisetin

Fu, X., Ma, J., Ma, F., Guo, S., Wang, X., Ye, L., Tang, Y., Qi, J., Zhang, W., & Ye, L. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167515 · Cited by 7 · see citing works

Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Pancreatic Cancer Cells

Lee, J. H., Lee, S. H., Lee, S. K., Choi, J. H., Lim, S., Kim, M.-S., Lee, K.-M., Lee, M. W., Ku, J., Kim, D.-H., et al. (2023) · Cancers · doi:10.3390/cancers15092642 · Cited by 7 · see citing works

Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in <scp>2D</scp> and <scp>3D</scp> Cell Culture Models

Serala, K., Bai, J., & Prince, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70222 · Cited by 6 · see citing works

Identification of key hub genes in pancreatic ductal adenocarcinoma: an integrative bioinformatics study

Bhattacharjee, K., Sengupta, A., Kumar, R., & Ghosh, A. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1536783 · Cited by 6 · see citing works

Clinical practice guidelines for the interventional treatment of advanced pancreatic cancer (5th edition)

Li, M. (2021) · Journal of interventional medicine · doi:10.1016/j.jimed.2021.08.001 · Cited by 6 · see citing works

Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi‐institutional analysis

Amirian, H., Dickey, E. M., Ogobuiro, I. C., Box, E. W., Shah, A., Martos, M. P., Patel, M. S., Wilson, G. C., Snyder, R. A., Parikh, A. A., et al. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27798 · Cited by 4 · see citing works

Sequential YAP1/FOSL1 silencing and epigenetic therapy to overcome stromal barriers in pancreatic cancer

Maietta, I., Domínguez-Arístegui, P., Álvarez, I. G., Atanes, O. R., Fontán, E. M. G., Teijeira, S., González‐Fernández, Á., & Simón‐Vázquez, R. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126155 · Cited by 5 · see citing works

Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma

Song, H., & Jiang, C. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2045943 · Cited by 4 · see citing works

Platforms for Personalized Polytherapeutics Discovery in COVID-19

Hopkins, C. E., Onweni, C. L., Zambito, V., Fairweather, D., McCormick, K., Ebihara, H., Caulfield, T. R., Zhang, Y. S., & Freeman, W. D. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.166945 · Cited by 4 · see citing works

Non-coding RNAs as biomarkers and therapeutic targets in pancreatic cancer: Clinical implications and translational perspectives

Carretero-Fernández, M., Ruiz-Durán, L., Onganer, P. U., Daniel, N., Yiannakopoulou, E. C., Otlu, B., García‐Verdejo, F. J., López-López, J. A., Ortega, F. G., Bonilla, M., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119394 · Cited by 3 · see citing works

Latest developments in chemotherapy for metastatic pancreatic cancer

Khan, A. K., Jain, A. G., Afridi, S., Wazir, M., Rao, J. S., & Ahmad, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819457-7.00006-2 · Cited by 2 · see citing works

Combinatorial cetuximab targeted polymeric nanocomplexes reduce PRC1 level and abrogate growth of metastatic hepatocellular carcinoma in vivo with efficient radionuclide uptake

Poojari, R. J., Mohanty, B. S., Kadwad, V. B., Suryawanshi, D., Chaudhari, P. R., Khade, B., Srivastava, R., Gupta, S., & Panda, D. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102529 · Cited by 2 · see citing works

Radiolabeled chemotherapeutics as a novel strategy for targeted cancer therapy: current insights and future perspectives

Jain, A., & Das, T. (2023) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-023-09250-3 · Cited by 2 · see citing works

Oral metronomic therapy of pancreatic cancer with gemcitabine and paclitaxel co-loaded in lecithin-based Self-Nanoemulsifying preconcentrate (LBSNEP)

Lin, C., Cheng, W.-T., Chen, T., Chen, T.-L., Sheu, M., & Lin, H.-L. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123370 · Cited by 1 · see citing works

Synergistic Effect of Anti-PD-L1 Treatment and CD8+ T-Cell Activating Nanotherapy in Pancreatic Ductal Adenocarcinoma Evaluated via 3D Mathematical Modeling

Goodin, D. A., Daunke, T., Beckinger, S., Krüger, S., Röcken, C., Sebens, S., & Frieboes, H. B. (2025) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000572 · Cited by 1 · see citing works

Diabetes-Driven Post-Translational Remodeling in Pancreatic Ductal Adenocarcinoma

Kavyashree, S., Harithpriya, K., Ganesan, K., & Ramkumar, K. M. (2026) · Cancers · doi:10.3390/cancers18101657 · Cited by 1 · see citing works

Trend of Adjuvant Radiation in Resected Pancreatic Ductal Adenocarcinoma: Evaluation of RTOG 0848 with a Large National Database

Dickey, E. M., Blansfield, J., Hoffman, R. L., Jiang, J. M., & Amini, N. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01492-0 · Cited by 1 · see citing works

Recent Advancements for the Management of Pancreatic Cancer: Current Insights

Ali, N., & Srivastava, N. (2021) · Current Cancer Therapy Reviews · doi:10.2174/1573394717666210625153256 · Cited by 1 · see citing works

Drug Combinations

Shyr, Z. A., Cheng, Y., & Zheng, W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00058-x · Cited by 1 · see citing works

Targeting pancreatic ductal adenocarcinoma: New therapeutic options for the ongoing battle

Malhotra, P., Palanisamy, R., & Falasca, M. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.09.004 · Cited by 1 · see citing works

Pyrvinium Pamoate Enhances the Anti-cancer Activities of Gemcitabine in Pancreatic CancerPreprint

Serala, K., Bai, J., & Prince, S. (2024) · Preprints.org · doi:10.20944/preprints202402.1726.v1

A Holistic View of the Biology of Pancreatic Cancer and Targeted Therapeutic Approaches to Treat the CancerPreprint

Munir, S., Ahmad, S., & Gul, A. (2021) · Preprints.org · doi:10.20944/preprints202102.0107.v1

Association of Estrogen and Progesterone with Ovarian Cancers

Mudassir, A. Q., Zafar, A., Zia, U., Saboor, R., Rasheed, T., & Soomro, S. B. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22168301

Precision medicine for PDAC immunotherapy

Ukwade, D., Osmani, K., Fernandez, L., Hussain, S., Nwachukwu, D., & Ali, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23523-8.00014-6

Overcoming immunotherapeutic drug resistance in pancreatic and colon cancers

Tavakoli, M., Raza, H., Ukwade, D., Nwachukwu, D., Mohamed, S., & Ali, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00028-9

The potential of small extracellular vesicles for pancreatic cancer therapy

Crow, R., Kehoe, O., & Hoskins, C. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00115c

Contrôle de l'oncogenicité de Kras et isoforme beta de PI3K dans la cancérogenèse du pancréas

Arcucci, S. (2019) · doi:10.70675/bd0f6cf8zac49z4e36zbe80z39b5e2b4e43a

Elucidation du rôle de la Ténascine-X dans la progression tumorale : focus sur la carcinogenèse pancréatique

Liot, S. (2021) · doi:10.70675/264bf0e9z97a7z4aaezaf51z5387f0dd8f4c

CURCUMIN ENHANCES CISPLATIN-INDUCED CYTOTOXICITY IN PANC-1 AND MIA PACA-2 PANCREATIC CANCER CELLS

PREDESCU, I.-A., Boru, C., Smeu, A., CORICOVAC, E.-D., HOINOIU, B., TĂNASE, A., & Dehelean, C. A. (2026) · FARMACIA · doi:10.31925/farmacia.2026.1.8

Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment

Tarannum, M., & Vivero-Escoto, J. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114357 · Cited by 76 · see citing works

A New Perspective for Pancreatic Ductal Adenocarcinoma Management: Diagnosis and Therapy Using Nanoparticle-Based Technology

de la Fuente, N., Artigas, V., Caruana, P., Rodríguez, F., & Céspedes, M. V. (2021) · JOP, journal of the pancreas

Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma

Yang, X., Lu, Y., Xu, J., Du, Y., & Yu, R. (2023) · Molecules · doi:10.3390/molecules28031506 · Cited by 12 · see citing works

Multimodal Therapies against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches toward Ultimate Nanomedicine Treatments

Conte, M., & Cauda, V. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200079 · Cited by 26 · see citing works

Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer

Bincoletto, V., Andreana, I., Stella, B., Modjtahedi, N., Arpicco, S., & Urbinati, G. (2026) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70067